Inserm Transfert and Innate Pharma enter into a partnership for the development of antibodies for the treatment of cancer
Inserm Transfert and Innate Pharma announce the execution of an agreement facilitating the development of antibodies in cancer, inflammation and auto-immunity. This partnership of a new kind will enable Innate Pharma to be informed of the discovery of promising antibody targets at an early stage, and in turn to collaborate with academic scientists to develop drug candidates directed to such targets. On Inserm’s side, it will accelerate the identification and validation of targets with market potential.
This agreement includes three main stages:
- Inserm Transfert will make available to Innate Pharma, for preliminary evaluation, information on early-stage antibody targets (within the scope of the agreement) discovered by Inserm academic laboratories;
- For targets selected by Innate Pharma following this preliminary evaluation, Inserm and Innate Pharma will implement a collaborative research program to advance and mature the project towards the development of a drug candidate. The partners will enter into an option agreement for a potential license of the target by Innate Pharma;
- At the end of the collaborative research program, Innate Pharma may exercise its option and enter into a licensing agreement.
Data generated during the collaboration for targets not retained by Innate Pharma will be the property of Inserm.
Other news from the department science
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous